CompletedNCT01786239
Omega-3 Added to Treatment for Early Schizophrenia
About this title
Read the official source — NCT01786239Medication studyAges 15–40United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 15 years to 40 years. Other eligibility criteria applied.
- Listed locations
- Glen OaksSee all locations and recruitment
Study information
Study start dateMay 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Delbert Robinson
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Locations
- United States
- Age range
- From 15 Years to 40 Years
- Official registry ID
- NCT01786239
- Official title
Show the full official title
Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Glen Oaks
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Delbert Robinson.
Did this study involve medication?
Yes. The study involved medication, including Risperidone, Omega-3 capsules and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 15 years to 40 years. Other eligibility criteria applied.
